South Korea Hemoglobinopathies Market Size, Share, and COVID-19 Impact Analysis, By Type (Thalassemia, Sickle Cell Disease, and Other Haemoglobin (Hb) Variants), By Diagnosis (Sickle Cell Disease Diagnosis, Thalassemia Therapeutics), and South Korea Hemoglobinopathies Market Insights, Industry Trend, Forecasts to 2035

  South Korea Hemoglobinopathies Market Insights Forecasts to 2035

• The South Korea Hemoglobinopathies Market Size Was Estimated at USD 251.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 13.67% from 2025 to 2035
• The South Korea Hemoglobinopathies Market Size is Expected to Reach USD 1030.0 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Hemoglobinopathies Market Size is anticipated to reach USD 1030.0 Million by 2035, growing at a CAGR of 13.67% from 2025 to 2035. The hemoglobinopathies market are the rising incidence of diseases including sickle cell disease and thalassemia, as well as a robust pipeline of products for treating hemoglobinopathies.

Market Overview

The market for diagnosing, treating, and managing inherited blood illnesses that are typified by aberrant hemoglobin production or structure is known as the hemoglobinopathies market. Chronic anemia and associated health issues are caused by these conditions, which include thalassemia and sickle cell disease. Growing public awareness of diseases, pro-business government regulations, and improvements in genetic testing and treatments are driving the market. Increased awareness, early diagnosis through newborn screening, and the development of targeted therapies are leading to better management and potentially curative treatments for hemoglobinopathies like sickle cell disease and thalassemia. Healthcare markets are expanding in several nations where hemoglobinopathies are highly prevalent. There are substantial business prospects to increase access to efficient therapies in these areas. To facilitate early diagnosis and prompt care, governments are implementing screening programs and conducting campaigns to increase public awareness of hemoglobinopathies, particularly in newborns.

Report Coverage

This research report categorizes the market for South Korea hemoglobinopathies market based on various segments and regions forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea hemoglobinopathies market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea hemoglobinopathies market.

Driving Factors

The rising global prevalence of genetic blood disorders such as thalassemia and sickle cell disease. Increased awareness, advancements in molecular diagnostics, and early screening technologies support timely diagnosis and treatment. Government initiatives and public health programs promote genetic counseling and prenatal testing. Additionally, the development of novel therapies, including gene therapy and bone marrow transplantation, enhances treatment outcomes.

Restraining Factors

Limited awareness in low-income regions, leading to delayed diagnosis and treatment. High costs associated with advanced therapies like gene editing and bone marrow transplants restrict accessibility. Additionally, the shortage of specialized healthcare professionals and inadequate infrastructure in some countries hinder effective disease management. Complex regulatory approval processes for new treatments slow market growth.        

Market Segmentation

The South Korea hemoglobinopathies market share is classified into type and diagnosis.

• The thalassemia segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea hemoglobinopathies market is segmented by type into thalassemia, sickle cell disease, and other haemoglobin (Hb) variants. Among these, the thalassemia segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The increasing awareness, improved diagnostic capabilities, and government initiatives promoting genetic screening. The rising number of carriers and advancements in prenatal testing contribute to early detection and management. Additionally, ongoing research, availability of better treatment options, and supportive healthcare infrastructure drive growth. The cultural emphasis on preventive care and the integration of genetic counseling in public health services.

• The sickle cell disease diagnosis segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea hemoglobinopathies market is segmented by diagnosis into sickle cell disease diagnosis, thalassemia therapeutics. Among these, the sickle cell disease diagnosis segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The increasing adoption of advanced diagnostic technologies like HPLC and molecular testing. Growing awareness about early detection and improved healthcare access have enhanced screening rates. Additionally, government-led initiatives and public health programs promote newborn and carrier screening. The demand for accurate, early-stage diagnosis to enable timely intervention and disease management continues to rise.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea hemoglobinopathies market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market

List of Key Companies

• GC Biopharma
• Yuhan Corporation
• Chong Kun Dang
• Hanmi Pharm
• Lotte Biologics
• GeneMatrix Inc.
• LegoChem Biosciences
• LG Chem Life Sciences
• MEDIPOST
• Genexine
• Helixmith
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea hemoglobinopathies market based on the below-mentioned segments:

South Korea Hemoglobinopathies Market, By Type

• Thalassemia
• Sickle Cell Disease
• Other Haemoglobin (Hb) Variants)

South Korea Hemoglobinopathies Market, By Diagnosis

• Sickle Cell Disease Diagnosis

Thalassemia Therapeutics